| First Author | Dong Y | Year | 2015 |
| Journal | J Clin Invest | Volume | 125 |
| Issue | 12 | Pages | 4349-64 |
| PubMed ID | 26571402 | Mgi Jnum | J:229826 |
| Mgi Id | MGI:5754657 | Doi | 10.1172/JCI80349 |
| Citation | Dong Y, et al. (2015) Motif mimetic of epsin perturbs tumor growth and metastasis. J Clin Invest 125(12):4349-64 |
| abstractText | Tumor angiogenesis is critical for cancer progression. In multiple murine models, endothelium-specific epsin deficiency abrogates tumor progression by shifting the balance of VEGFR2 signaling toward uncontrolled tumor angiogenesis, resulting in dysfunctional tumor vasculature. Here, we designed a tumor endothelium-targeting chimeric peptide (UPI) for the purpose of inhibiting endogenous tumor endothelial epsins by competitively binding activated VEGFR2. We determined that the UPI peptide specifically targets tumor endothelial VEGFR2 through an unconventional binding mechanism that is driven by unique residues present only in the epsin ubiquitin-interacting motif (UIM) and the VEGFR2 kinase domain. In murine models of neoangiogenesis, UPI peptide increased VEGF-driven angiogenesis and neovascularization but spared quiescent vascular beds. Further, in tumor-bearing mice, UPI peptide markedly impaired functional tumor angiogenesis, tumor growth, and metastasis, resulting in a notable increase in survival. Coadministration of UPI peptide with cytotoxic chemotherapeutics further sustained tumor inhibition. Equipped with localized tumor endothelium-specific targeting, our UPI peptide provides potential for an effective and alternative cancer therapy. |
